biostudies-literatureMauck MCNational Institute of Arthritis and Musculoskeletal and Skin DiseasesThe Back Pain ConsortiumNCCIH NIH HHSNIDA NIH HHSNIMHD NIH HHSNINDS NIH HHSNational Institutes of HealthNIAMS NIH HHSDepartment of DefenseNIH HHS538-553https://www.ebi.ac.uk/biostudies/studies/S-EPMC12405758biostudies-literatureUnknown26(9)<h4>Objective</h4>Chronic low back pain (cLBP) is a common condition that impacts quality of life and function. There are many evidence-based treatments to address cLBP; however, treatment effects are modest, perhaps in part due to individual variation in treatment response. The Biomarkers for Evaluating Spine Treatments (BEST) trial was designed as the collaborative centerpiece of the Back Pain Consortium (BACPAC) research program. This consortium was sponsored by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) as part of the Helping to End Addiction Long-term (HEAL) Initiative.<h4>Design</h4>The BEST trial was a sequential multiple assignment randomized trial (SMART) designed with the primary goal of identifying in whom different treatments show optimal Pain medicine (Malden, Mass.)The design and rationale of the Biomarkers for Evaluating Spine Treatments trial: a sequential multiple assignment randomized trial.PMC124057581K23AT011389-01A1R21 MD016467K23 AT011389W81XWH-21-PRMRP-CTA [PR212158]RM1NS128956-01A1U24 AR0767301R21MD016467-01U24AR076730R01DA058694-01RM1 NS128956R01 NS135833R01NS135833-01A1R01 DA058694Chadwick ALKidwell KMJones Berkeley SNapadow VJChidgey BWilson LMageswaran PLotz JCPeltier SIvanova AKosorok MRMarras WSLobo RHarte SFritz JMBatorsky ACastellanos JBell KMChen LHurley RWPatel KVWeber KAPiva SRPsioda MGunn CAWilliams DAHoffmeyer AFields AJO'Neill CSperger JSowa GAMcCumber MRundell SDAnstrom KJWasan ADDalton DCarey TSKnapik GGMao JMitchell UHBailey JFBrooks AKSchneider MJDufour JSMajumdar SMcLean SASchrepf AGreco CMZeidan FBarth KSHassett ALZhao BWallace MSGoolsby RWMehling WBorckardt JJHarris RERowland BMauck MCVo NKaplan CClauw DJBowden AEWeaver TEKurillo GMackey SBagaason SfalseThe design and rationale of the Biomarkers for Evaluating Spine Treatments trial: a sequential multiple assignment randomized trial.<h4>Objective</h4>Chronic low back pain (cLBP) is a common condition that impacts quality of life and function. There are many evidence-based treatments to address cLBP; however, treatment effects are modest, perhaps in part due to individual variation in treatment response. The Biomarkers for Evaluating Spine Treatments (BEST) trial was designed as the collaborative centerpiece of the Back Pain Consortium (BACPAC) research program. This consortium was sponsored by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) as part of the Helping to End Addiction Long-term (HEAL) Initiative.<h4>Design</h4>The BEST trial was a sequential multiple assignment randomized trial (SMART) designed with the primary goal of identifying in whom different treatments show optimal 2025-01-01T00:00:00Z2025 Sep2026-07-15T14:25:30.933Z2026-07-05T03:12:25.238ZS-EPMC124057584020545510.1093/pm/pnaf032